Edelman M - Search Results

1

Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial.

Hamy AS, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, Brain E, Pistilli B, Marty M, Espié M, Benchimol G, Laas E, Laé M, Asselain B, Aouchiche B, Edelman M, Reyal F. Hamy AS, et al. Among authors: edelman m. J Clin Oncol. 2019 Mar 10;37(8):624-635. doi: 10.1200/JCO.18.00636. Epub 2019 Jan 31. J Clin Oncol. 2019. PMID: 30702971 Free PMC article.

2

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Lara PN Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, Gandara DR; Southwest Oncology Group. Lara PN Jr, et al. J Clin Oncol. 2008 Jan 20;26(3):463-7. doi: 10.1200/JCO.2007.13.0344. J Clin Oncol. 2008. PMID: 18202421 Clinical Trial.

3

Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.

Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ. Edelman MJ, et al. J Clin Oncol. 2008 Feb 20;26(6):848-55. doi: 10.1200/JCO.2007.13.8081. J Clin Oncol. 2008. PMID: 18281656 Clinical Trial.

4

Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304.

Edelman MJ, Hodgson L, Wang X, Christenson R, Jewell S, Vokes E, Kratzke R. Edelman MJ, et al. J Thorac Oncol. 2011 Nov;6(11):1902-6. doi: 10.1097/JTO.0b013e31822a7383. J Thorac Oncol. 2011. PMID: 21964530 Free PMC article. Clinical Trial.

5

CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.

Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, Kratzke R. Edelman MJ, et al. J Thorac Oncol. 2012 Apr;7(4):649-54. doi: 10.1097/JTO.0b013e31824a8db0. J Thorac Oncol. 2012. PMID: 22425913 Free PMC article. Clinical Trial.

6

Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer.

Edelman MJ, Hodgson L, Wang X, Kratzke RA, Vokes EE. Edelman MJ, et al. J Clin Oncol. 2012 Jun 1;30(16):2019-20; author reply 2020. doi: 10.1200/JCO.2011.41.4581. Epub 2012 Apr 2. J Clin Oncol. 2012. PMID: 22473168 Free PMC article. No abstract available.

7

Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.

Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA. Jänne PA, et al. Among authors: edelman mj. J Clin Oncol. 2012 Jun 10;30(17):2063-9. doi: 10.1200/JCO.2011.40.1315. Epub 2012 Apr 30. J Clin Oncol. 2012. PMID: 22547605 Free PMC article. Clinical Trial.

8

Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.

Edelman MJ, Schneider CP, Tsai CM, Kim HT, Quoix E, Luft AV, Kaleta R, Mukhopadhyay P, Trifan OC, Whitaker L, Reck M. Edelman MJ, et al. J Clin Oncol. 2013 Jun 1;31(16):1990-6. doi: 10.1200/JCO.2012.45.3282. Epub 2013 Apr 15. J Clin Oncol. 2013. PMID: 23589560 Clinical Trial.

9

Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.

Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, Hensing TA, Rowland K, Schiller J, Ding K, Shepherd FA. Goss GD, et al. J Clin Oncol. 2013 Sep 20;31(27):3320-6. doi: 10.1200/JCO.2013.51.1816. Epub 2013 Aug 26. J Clin Oncol. 2013. PMID: 23980091 Free PMC article. Clinical Trial.

10

The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.

Kim GJ, Koshy M, Hanlon AL, Horiba MN, Edelman MJ, Burrows WM, Battafarano RJ, Suntharalingam M. Kim GJ, et al. Among authors: edelman mj. Am J Clin Oncol. 2016 Apr;39(2):136-41. doi: 10.1097/COC.0000000000000036. Am J Clin Oncol. 2016. PMID: 24487417 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

557 results

Search Page

Filters